202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer
M. Oliveira, J.M. Cejalvo Andujar, Mireia Margelí Vila, P. Tolosa Ortega et autres
es, us (code pays fourni par la source)